FRE.DE
Stock Details
FRE.DE is Fresenius SE & Co. KGaA's stock. Stock exchange XETRA (Currency EUR). Average price in 50 days is 25.10€. Average daily volumn in 3 months 1.49M. Market cap 12.31B
Stock symbol : FRE.DE. Exchange : XETRA. Currency : EUR Lastest price : 21.85€. Total volume : 2.38M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Fresenius SE & Co. KGaA (FRE.DE)
Last Price
21.85€Change
-0.70Volume
2.38M
| Previous Close | 22.55 |
| Open | 22.77 |
| Day Range | 21.84-22.77 |
| Bid | 21.87 x N/A |
| Ask | 21.88 x N/A |
| Volume | 2.38M |
| Average Volume | 1.49M |
| Market Cap | 12.31B |
| Beta | 1.11 |
| 52 Week Range | 21.84-42.50 |
| Trailing P/E | 7.16 |
| Foward P/E | 6.04 |
| Dividend (Yield %) | 3.94% |
| Ex-Dividend Date | 2022-05-16 |
Financial Details
Organization
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi s... egment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Market Cap:
12.31BRevenue:
37.52BTotal Assets:
71.96BTotal Cash:
2.76B
News about "Fresenius SE & Co. KGaA"
Fresenius SE & Co KGaA
Source from : Reuters - 2 days ago
Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for ...See details»
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Receives Average Recommendation of “Hold” from Analysts
Source from : Defense World - 7 days ago
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) has received an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. Four ...See details»
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives New Coverage from Analysts at StockNews.com
Source from : Defense World - 16 hours ago
StockNews.com started coverage on shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the ...See details»
DGAP-DD: Fresenius SE & Co. KGaA english
Source from : Business Insider - 26 days ago
Archive at www.dgap.de 77689 29.08.2022 CET/CEST SHARE THIS POST Fresenius NewsMORE Related Stocks Find News News Indices Commodities Currencies Stocks ...See details»
Fresenius Medical Care AG & Co. KGaA ADR
Source from : Wall Street Journal - 11 days ago
Fresenius Medical Care AG & Co. KGaA, Fresenius Management SE, Else Kröner-Fresenius-Stiftung Dorothea Wenzel Member-Supervisory Board Fresenius Medical Care AG & Co. KGaA, H. Lundbeck A/S ...See details»
Fresenius SE
Source from : Barron's - 28 days ago
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following ...See details»
Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim - fpgk)
Source from : The Bakersfield Californian - 18 days ago
Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United ...See details»
Germany: Fresenius taps bond markets for €750m over five years
Source from : laingbuissonnews - 11 days ago
Fresenius Medical Care, a leading global provider of products and services for renal diseases, has placed €750m of five-year bonds. The bonds pay an annual coupon of 3.875% and were priced at 99.635% ...See details»
Fresenius Kidney Care Celebrates Nephrology Nurses Week with The CARE Award
Source from : Yahoo Finance - 12 days ago
Sept. 12, 2022 /PRNewswire/ -- Fresenius Kidney Care, the nation's leading provider of kidney care services, is pleased to announce its new annual recognition program to honor frontline nephrology ...See details»
Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange
Source from : WSIL-TV - 11 days ago
Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance ...See details»
Pain Management Market Size Will Achieve USD 83,348 Million by 2030 growing at 6.5% CAGR - Exclusive Report by Acumen Research and Consulting
Source from : Benzinga.com - 25 days ago
The Global Pain Management Market is anticipated to grow at a CAGR of around 6.5% during the forecast period 2022 to 2030 ...See details»
Fresenius Kabi, Samsung Bioepis lock horns again over Humira biosimilar
Source from : lawyerly - 10 days ago
Please login to bookmark Username or Email Address Password Remember Me German biotech Fresenius Kabi has struck back at Samsung Bioepis’s latest attack on […]See details»
Heparin Market Share, Size, Industry Demand, Growth Rate, SWOT Analysis, and Business Development by 2028
Source from : MarketWatch - 12 days ago
The global “Heparin Market Size" is expected to rise with an impressive CAGR and generate the highest revenue by ...See details»
Physiological Saline Market To See Strong Growth Momentum | Baxter, Fresenius Kabi, Hospira
Source from : MENAFN - 11 days ago
Physiological Saline Market PORTLAND, OREGON, UNITED STATES, September 13, 2022 /EINPresswire.com / -- Allied Market Research Analyst hav ...See details»